We observed a marked increase of Sema3C in glioblastomas compared to lower grade (i.e., WHO grades I, II, and III) astrocytomas (Fig. 1) indicating that the aberrant expression of Sema3C may be strongly associated with the advancement of glioma malignancy. Here, SEMA3C is linked to glioblastoma.